Exclusion Criteria:~* Hepatic impairment defined as Child-Pugh class of A or more severe liver impairment.~*
Other neurodegenerative diseases and causes of dementias, including Parkinson's disease and Huntington's
disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive
Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure hydrocephalus).~*
History of a major depressive episode within the past 6 months of screening.~* Insulin-dependent diabetes or
uncontrolled diabetes with HbA1c value >8.0 %.~* Cancer or a malignant tumor within the past 3 years, except
patients who underwent potentially curative therapy with no evidence of recurrence for >3 years. Patients with
stable prostate cancer or non-melanoma skin cancers are not excluded.~* Participation in another clinical trial
for an investigational agent and having taken at least one dose of study medication, unless confirmed as having
been on placebo, within 12 weeks prior to screening. The end of a previous investigational trial is defined as
the date of the last dose of an investigational agent.
